Oxford BioMedica Announces Collaboration With Immune Design Corp.

26 September 2012

Oxford, UK and Seattle, WA, USA – 27 September 2012: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE: OXB), the leading gene-based biopharmaceutical company, has signed a master services agreement with Immune Design Corp. (Immune Design), a privately held biotechnology company based in Seattle, Washington (USA), which is developing a therapeutic vaccine utilising a lentiviral-based vector in order to target cancer and other chronic diseases.

The collaboration aims to leverage Oxford BioMedica’s expertise in lentiviral vector clinical development by focusing on the design and validation of custom analytical methods, in order to facilitate the future clinical development path for Immune Design’s pre-clinical therapeutic vaccine candidate for the treatment of cancer.

John Dawson, Chief Executive Officer of Oxford BioMedica, commented: “Having successfully initiated ground-breaking clinical studies with our own gene therapy products, we pride ourselves on our translational expertise and look forward to supporting Immune Design with the transition of its therapeutic cancer vaccine into a first-in-man study.”

Carlos Paya, Chief Executive Officer of Immune Design, said: “We are very excited to be working with Oxford BioMedica on the development of our lentiviral-based vector.  By capitalising on Oxford BioMedica’s expertise in lentiviral vector products, we plan to rapidly advance our novel vector to clinic for the treatment of several cancer indications.”